Verastem, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.0 months). See all sponsors →
Open Verastem, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| RAMP 201 NCT04625270 |
P2 | Active, not recruiting | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | 225 | 2024-11-15 (+18 mo) |
| RAMP201J NCT06682572 |
P2 | Active, not recruiting | Low Grade Serous Ovarian Cancer; Ovarian Cancer | 16 | 2025-12 |
| RAMP203 NCT05074810 |
P1/2 | Active, not recruiting | Non Small Cell Lung Cancer; KRAS Activating Mutation | 153 | 2026-06 (+30 mo) |
| RAMP205 NCT05669482 |
P1/2 | Active, not recruiting | KRAS Activating Mutation; Metastatic Cancer | 40 | 2026-08-31 (+15 mo) |
| TARGET-D 203 NCT07659795 |
P2 | Recruiting | Colorectal Cancer | 150 | 2027-06 |
| TARGET-D 202 NCT07659782 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 105 | 2027-06 |
| VS-7375 NCT07644559 |
P2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS | 185 | 2027-06 |
| avutometinib + defactininb combination NCT07747506 |
P2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | 2 | 2027-08-01 |
| RAMP 301 NCT06072781 |
P3 | Recruiting | Low Grade Serous Ovarian Cancer | 270 | 2028-10-15 |
| VS-7375 NCT07020221 |
P1/2 | Recruiting | Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer | 616 | 2028-12 (+3 mo) |